Ingrid Mayer, MD
Vanderbilt-Ingram Cancer Center
13
8
6
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+16 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (13)
Showing 10 of 13 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Norman Wolmark, MD
NSABP Foundation Inc
Shared therapeutic areas:
Worked with same sponsors:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
John D. Hainsworth, MD
SCRI Development Innovations, LLC
Shared therapeutic areas:
Worked with same sponsors:
Aminah Jatoi, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Shared therapeutic areas:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (13)
Showing 13 of 13 trials
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
All 13 trials loaded